Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#161 / 200 Total
RCRT - Recruiter.com Group Inc - Stock Price Chart
TickerRCRT [NASD]
CompanyRecruiter.com Group Inc
CountryUSA
IndustryStaffing & Employment Services
Market Cap2.28MEPS (ttm)-5.94
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y69.04%
P/S0.40EPS next 5Y-
P/B2.41EPS Q/Q85.56%
Dividend-Sales Q/Q-96.00%
Insider Own8.11%Inst Own7.96%
Insider Trans0.00%Inst Trans-
Short Float1.94%EarningsNov 20/a
Analyst Recom1.00Target Price30.00
Avg Volume34.05K52W Range1.04 - 7.50
Recruiter.com Group, Inc. operates an on-demand recruiting platform that aims to deliver the right talent to both small and large businesses. The platform is powered by virtual teams of Recruiters On Demand and Video and Artificial Intelligence (AI) job-matching technology. It provides employers access to independent recruiters and utilizes an innovative web platform, with integrated AI-driven candidate to job matching and video screening software to source qualified talent. The company was founded by Michael Jay Solomon, Ashley Saddul, and Miles Jennings on July 28, 2008 and is headquartered in Bristol, CT.
FWBI - First Wave BioPharma Inc - Stock Price Chart
TickerFWBI [NASD]
CompanyFirst Wave BioPharma Inc
CountryUSA
IndustryBiotechnology
Market Cap5.77MEPS (ttm)-86.07
P/E-EPS this Y91.42%
Forward P/E-EPS next Y56.88%
PEG-EPS past 5Y73.53%
P/S-EPS next 5Y-
P/B1.23EPS Q/Q96.66%
Dividend-Sales Q/Q-
Insider Own3.56%Inst Own4.07%
Insider Trans-4.64%Inst Trans-
Short Float2.05%Earnings-
Analyst Recom2.00Target Price36.00
Avg Volume96.74K52W Range2.42 - 62.40
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAPIRSTEIN JAMESChairman and CEOApr 01 '24Sale4.2317473637,105Apr 03 05:14 PM
Romano SarahChief Financial OfficerApr 01 '24Sale4.237531719,111Apr 03 05:13 PM
SAPIRSTEIN JAMESChairman and CEOMar 15 '24Sale4.961,8879,36037,279Mar 19 04:13 PM
Romano SarahChief Financial OfficerMar 15 '24Sale4.961,1205,55519,186Mar 19 04:10 PM
SAPIRSTEIN JAMESChairman, President and CEOJan 12 '24Sale4.2016669739,166Jan 17 04:01 PM
SLDB - Solid Biosciences Inc - Stock Price Chart
TickerSLDB [NASD]
CompanySolid Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap360.23MEPS (ttm)-4.83
P/E-EPS this Y46.17%
Forward P/E-EPS next Y-6.37%
PEG-EPS past 5Y32.21%
P/S-EPS next 5Y-
P/B1.54EPS Q/Q-28.76%
Dividend-Sales Q/Q-
Insider Own19.88%Inst Own58.87%
Insider Trans132.63%Inst Trans-0.61%
Short Float3.47%EarningsMar 13/b
Analyst Recom1.62Target Price16.29
Avg Volume261.90K52W Range1.81 - 15.05
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ganot IlanDirectorJan 29 '24Sale7.991391,1118,416Jan 30 05:20 PM
PERCEPTIVE ADVISORS LLCDirectorJan 11 '24Buy5.533,410,71318,861,2436,833,539Jan 12 05:15 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJan 11 '24Buy5.53904,1605,000,0054,192,216Jan 12 05:01 PM
Tan KevinCFO & TreasurerJan 09 '24Sale8.203,93532,2679,308Jan 11 05:43 PM
Ganot IlanDirectorJan 03 '24Sale5.301,1426,0528,167Jan 05 07:04 PM
NPCE - NeuroPace Inc - Stock Price Chart
TickerNPCE [NASD]
CompanyNeuroPace Inc
CountryUSA
IndustryMedical Devices
Market Cap401.22MEPS (ttm)-1.28
P/E-EPS this Y8.62%
Forward P/E-EPS next Y15.41%
PEG-EPS past 5Y-0.33%
P/S6.13EPS next 5Y-
P/B18.82EPS Q/Q48.44%
Dividend-Sales Q/Q40.84%
Insider Own52.25%Inst Own30.25%
Insider Trans-4.18%Inst Trans-1.25%
Short Float0.71%EarningsMay 08/a
Analyst Recom1.29Target Price17.29
Avg Volume106.88K52W Range3.80 - 18.15
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerApr 24 '24Sale14.061,78125,0413,435,541Apr 26 05:01 PM
ORBIMED ADVISORS LLC10% OwnerApr 23 '24Sale14.2921,791311,3933,437,322Apr 23 06:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 22 '24Sale14.0524,609345,7563,459,113Apr 23 06:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 19 '24Sale14.0218,253255,9073,483,722Apr 23 06:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 18 '24Sale14.062,62336,8793,501,975Apr 18 05:10 PM
CRGX - CARGO Therapeutics Inc - Stock Price Chart
TickerCRGX [NASD, RUT]
CompanyCARGO Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap808.66MEPS (ttm)-
P/E-EPS this Y66.73%
Forward P/E-EPS next Y11.91%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.09EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own34.64%Inst Own66.56%
Insider Trans24.31%Inst Trans-
Short Float13.21%EarningsMar 21/a
Analyst Recom1.00Target Price31.00
Avg Volume311.01K52W Range13.14 - 33.92
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Third Rock Ventures V, L.P.10% OwnerNov 14 '23Buy15.001,333,33319,999,9951,807,119Nov 14 07:08 PM
PERCEPTIVE ADVISORS LLCFormer 10% OwnerNov 14 '23Buy15.00666,6669,999,9902,912,835Nov 14 04:32 PM
Samsara BioCapital GP, LLC10% OwnerNov 14 '23Buy15.00666,6669,999,9904,121,689Nov 16 07:39 PM
GPRO - GoPro Inc. - Stock Price Chart
TickerGPRO [NASD, RUT]
CompanyGoPro Inc.
CountryUSA
IndustryConsumer Electronics
Market Cap283.28MEPS (ttm)-0.34
P/E-EPS this Y47.82%
Forward P/E18.60EPS next Y195.82%
PEG-EPS past 5Y15.00%
P/S0.28EPS next 5Y10.00%
P/B0.50EPS Q/Q-180.81%
Dividend-Sales Q/Q-7.97%
Insider Own19.57%Inst Own51.55%
Insider Trans-0.58%Inst Trans-4.14%
Short Float5.34%EarningsMay 07/a
Analyst Recom3.50Target Price2.20
Avg Volume2.08M52W Range1.67 - 4.45
GoPro, Inc. engages in manufacturing and selling cameras and camera accessories. It provides mountable and wearable cameras and accessories, which it refers to as capture devices. Its product brands include HERO9 Black, HERO8 Black, Max, HERO7 Black, HERO7 Silver, GoPro Plus, and GoPro App. The company was founded by Nicholas Woodman in 2002 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCGEE BRIANEVP, CFO and COOFeb 16 '24Sale2.40121,441291,264288,424Feb 20 04:03 PM
Jahnke DeanSVP, Global Sales, CM, REFeb 16 '24Sale2.4127,84967,094267,651Feb 20 04:06 PM
Lafrades CharlesChief Accounting OfficerFeb 16 '24Sale2.418,16619,69292,989Feb 20 04:07 PM
MCGEE BRIANEVP, CFO and COONov 16 '23Sale3.499,51133,147379,809Nov 17 04:04 PM
Saltman Eve T.SVP, Corp/Bus Dev, CLO, SecNov 16 '23Sale3.485,46619,046212,928Nov 17 04:05 PM
OCEA - Ocean Biomedical Inc. - Stock Price Chart
TickerOCEA [NASD, RUT]
CompanyOcean Biomedical Inc.
CountryUSA
IndustryBiotechnology
Market Cap52.15MEPS (ttm)-3.83
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-587.66%
Dividend-Sales Q/Q-
Insider Own74.86%Inst Own13.49%
Insider Trans0.00%Inst Trans2.64%
Short Float7.39%Earnings-
Analyst Recom1.00Target Price18.50
Avg Volume6.83M52W Range0.52 - 12.08
Apr-24-24 04:51PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K (GlobeNewswire)
Mar-28-24 01:15PM 13 Hot Stocks to Invest in According to Wall Street Analysts (Insider Monkey) -6.77%
08:01AM Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL (GlobeNewswire)
Mar-24-24 03:52PM 5 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-05-24 08:30AM Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments (GlobeNewswire) +28.92%
Feb-29-24 08:01AM Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting (GlobeNewswire) +14.29%
Dec-05-23 09:45AM EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody (Benzinga)
08:15AM Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody (GlobeNewswire)
Nov-29-23 05:41PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) -8.95%
Nov-14-23 08:01AM Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics (GlobeNewswire) -15.36%
Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.
AMPX - Amprius Technologies Inc - Stock Price Chart
TickerAMPX [NYSE, RUT]
CompanyAmprius Technologies Inc
CountryUSA
IndustryElectrical Equipment & Parts
Market Cap189.72MEPS (ttm)-0.39
P/E-EPS this Y-2.27%
Forward P/E-EPS next Y11.89%
PEG-EPS past 5Y-
P/S32.16EPS next 5Y-
P/B2.68EPS Q/Q-95.82%
Dividend-Sales Q/Q242.89%
Insider Own83.47%Inst Own4.73%
Insider Trans-2.26%Inst Trans-
Short Float9.08%EarningsMay 09/a
Analyst Recom1.29Target Price10.50
Avg Volume605.31K52W Range1.56 - 10.63
Amprius Technologies, Inc. engages in the manufacture and distribution of batteries. Its products are primarily used for existing and emerging aviation applications, including unmanned aerial systems. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bornstein JonathanPresident of Amprius LabApr 12 '24Option Exercise0.051,007,86750,3931,566,797Apr 15 05:53 PM
Bornstein JonathanPresident of Amprius LabApr 02 '24Option Exercise0.05125,9836,299684,913Apr 03 04:13 PM
Bornstein JonathanPresident of Amprius LabApr 02 '24Sale2.38125,983299,613558,930Apr 03 04:13 PM
Bornstein JonathanPresident of Amprius LabMar 06 '24Option Exercise0.0540,2002,01040,200Mar 07 05:36 PM
Bornstein JonathanPresident of Amprius LabMar 06 '24Sale2.7840,200111,5790Mar 07 05:36 PM
LUMO - Lumos Pharma Inc - Stock Price Chart
TickerLUMO [NASD]
CompanyLumos Pharma Inc
CountryUSA
IndustryBiotechnology
Market Cap24.49MEPS (ttm)-4.19
P/E-EPS this Y34.26%
Forward P/E-EPS next Y27.51%
PEG-EPS past 5Y20.27%
P/S11.95EPS next 5Y15.20%
P/B0.90EPS Q/Q-17.01%
Dividend-Sales Q/Q61.33%
Insider Own39.29%Inst Own25.28%
Insider Trans-0.08%Inst Trans7.93%
Short Float5.83%EarningsMar 07/a
Analyst Recom1.00Target Price22.50
Avg Volume19.70K52W Range2.41 - 4.55
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKew John C.Chief Scientific OfficerApr 03 '24Sale2.772,2146,14417,153Apr 03 05:10 PM
McKew John C.Chief Scientific OfficerFeb 06 '24Sale3.034381,32818,403Feb 07 05:22 PM
McKew John C.Chief Scientific OfficerAug 02 '23Sale3.213,40710,91918,707Aug 03 04:58 PM
KRRO - Korro Bio Inc. - Stock Price Chart
TickerKRRO [NASD]
CompanyKorro Bio Inc.
CountryUSA
IndustryBiotechnology
Market Cap489.14MEPS (ttm)-63.36
P/E-EPS this Y82.75%
Forward P/E-EPS next Y3.18%
PEG-EPS past 5Y-11.67%
P/S-EPS next 5Y-
P/B2.88EPS Q/Q80.13%
Dividend-Sales Q/Q-
Insider Own48.95%Inst Own58.82%
Insider Trans4.71%Inst Trans-28.25%
Short Float3.28%EarningsMar 26/a
Analyst Recom1.00Target Price130.00
Avg Volume33.61K52W Range4.57 - 97.91
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Atlas Venture Opportunity Fund10% OwnerApr 22 '24Buy56.0017,857999,992195,074Apr 23 05:23 PM
New Enterprise Associates 17, 10% OwnerApr 22 '24Buy56.0017,857999,9921,090,793Apr 24 05:00 PM
BASKETT FOREST10% OwnerApr 22 '24Buy56.0017,857999,9921,090,793Apr 24 05:00 PM
Chang Carmen10% OwnerApr 22 '24Buy56.0017,857999,9921,090,793Apr 24 05:00 PM
Florence Anthony A. Jr.10% OwnerApr 22 '24Buy56.0017,857999,9921,090,793Apr 24 05:00 PM
110121314151617181920